Extracellular vesicles derived from amniotic fluid stem cells normalize glomerular function during progressive kidney disease.
来自羊水干细胞的细胞外囊泡在进行性肾脏疾病期间使肾小球功能正常化。
基本信息
- 批准号:10348192
- 负责人:
- 金额:$ 52.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:Angiotensin IIAngiotensin-Converting Enzyme InhibitorsAnimal ModelAreaBiopsyBloodCell physiologyCellsCellular MorphologyCellular biologyChronic Kidney FailureComplexDataDepositionDevelopmentDialysis procedureDiseaseDisease ProgressionDown-RegulationEndothelial CellsEndotheliumGenomicsGenotypeGoalsHereditary nephritisHistologicHumanImmune responseImmunizationIn VitroInjectionsInjuryInvestigationKidney DiseasesKnowledgeLeadLongevityMaintenanceMedicalModelingMolecularMorbidity - disease rateMusPathway interactionsPatientsPharmaceutical PreparationsPhasePhenotypePlayProcessProteinsProteinuriaRenal functionRenal glomerular diseaseRoleSamplingSchemeSignal PathwaySignal TransductionStructureSurfaceTestingTherapeutic AgentsTherapeutic EffectTherapeutic StudiesTransforming Growth Factor betaTransgenic OrganismsTransplantationUltrafiltrationUrineVascular Endothelial Growth FactorsWorkamniotic fluid derived stem cellbasecell injuryeffective therapyextracellular vesiclesglomerular basement membraneglomerular endotheliumglomerular filtrationglomerular functionimprovedin vivoinnovationinsightkidney fibrosismouse modelnovelnovel therapeuticspodocytepreventprogramsrenal damagerepairedside effectstandard of caretooltranscriptomics
项目摘要
During the progression of most chronic kidney diseases (CKD) podocytes and glomerular endothelial cells (GEC)
are irreversibly damaged. Injury to these cells or changes within the composition of the glomerular basement
membrane lead to alterations of the structure and function of the glomerular filtration barrier (GFB). Re-
establishing GFB function by stimulating endogenous repair mechanisms could slow kidney disease
progression.
Data presented in this proposal show that extracellular vesicles derived from human amniotic fluid stem cells
(hAFSC-EVs) are renoprotective in vivo in our animal model of CKD, Alport Syndrome (AS). No side effects or
stimulation of an immune response occurred. These EVs can activate repair mechanisms in glomerular cells by
cargo transfer. Specifically, they modulate the levels of miR-93 in both podocytes and GEC. miR-93 plays a key
role in CKD since changes in its expression level are associated with the development of renal damage and
fibrosis; specifically, miR-93 expression is decreased in mouse and human AS glomeruli and urine samples and
hEVs can restore miR-93 levels to normal. We hypothesize that hEVs can re-establish glomerular function
by preventing further glomerular injury, thus minimizing renal disease progression. Using transgenic
Alport mice, EVs of human origin, and human AS biopsies combined with an innovative spatial transcriptomics
approach, we will study the EV mechanism of action with specific focus on the ability of the EV/miR-93 axis to
“re-program” cellular signaling networks that regulate glomerular cell biology. We also aim to evaluate the
disease modifying capability of hEVs at different AS stages (Aim 1). Finally, we aim to study the molecular
signaling pathway changes within the glomerulus during disease progression with specific focus on GEC and to
validate these data in human AS biopsies (Aim 2).
Successful completion of this proposal will provide novel insights into the key factors critical for maintenance of
glomerular structure and function. Importantly, this knowledge would likely be applicable to other forms of CKD
and possibly will facilitate the discovery of new therapeutic agents tailored specifically to minimize glomerular
damage.
在大多数慢性肾脏疾病(CKD)进展过程中足细胞和肾小球内皮细胞(GEC)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Laura Perin其他文献
Laura Perin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Laura Perin', 18)}}的其他基金
Extracellular vesicles derived from amniotic fluid stem cells normalize glomerular function during progressive kidney disease.
来自羊水干细胞的细胞外囊泡在进行性肾脏疾病期间使肾小球功能正常化。
- 批准号:
10549376 - 财政年份:2020
- 资助金额:
$ 52.53万 - 项目类别:
Extracellular vesicles derived from amniotic fluid stem cells normalize glomerular function during progressive kidney disease.
来自羊水干细胞的细胞外囊泡在进行性肾脏疾病期间使肾小球功能正常化。
- 批准号:
9981313 - 财政年份:2020
- 资助金额:
$ 52.53万 - 项目类别:
相似海外基金
Utility of Centrally Acting Angiotensin Converting Enzyme Inhibitors to slow the progression of Dementia
中枢作用血管紧张素转换酶抑制剂减缓痴呆进展的效用
- 批准号:
10259832 - 财政年份:2020
- 资助金额:
$ 52.53万 - 项目类别:
Utility of Centrally Acting Angiotensin Converting Enzyme Inhibitors to slow the progression of Dementia
中枢作用血管紧张素转换酶抑制剂减缓痴呆进展的效用
- 批准号:
10642850 - 财政年份:2020
- 资助金额:
$ 52.53万 - 项目类别:
Utility of Centrally Acting Angiotensin Converting Enzyme Inhibitors to slow the progression of Dementia
中枢作用血管紧张素转换酶抑制剂减缓痴呆进展的效用
- 批准号:
10408178 - 财政年份:2020
- 资助金额:
$ 52.53万 - 项目类别:
Evaluating the synergistic effects of HMG-CoA reductase inhibitors and angiotensin converting enzyme inhibitors in a rabbit model of aortic valve sclerosis using computed tomography and magnetic resonance imaging.
使用计算机断层扫描和磁共振成像评估 HMG-CoA 还原酶抑制剂和血管紧张素转换酶抑制剂在主动脉瓣硬化兔模型中的协同作用。
- 批准号:
183194 - 财政年份:2009
- 资助金额:
$ 52.53万 - 项目类别:
Studentship Programs
Potential role for angiotensin-converting enzyme inhibitors in the treatment of patients with normal-tension glaucoma
血管紧张素转换酶抑制剂在治疗正常眼压性青光眼患者中的潜在作用
- 批准号:
20592078 - 财政年份:2008
- 资助金额:
$ 52.53万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PREVENTION OF EVENTS WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS
使用血管紧张素转换酶抑制剂预防事件
- 批准号:
6304989 - 财政年份:1999
- 资助金额:
$ 52.53万 - 项目类别:
PREVENTION OF EVENTS WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS
使用血管紧张素转换酶抑制剂预防事件
- 批准号:
6114904 - 财政年份:1998
- 资助金额:
$ 52.53万 - 项目类别:
PREVENTION OF EVENTS WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS
使用血管紧张素转换酶抑制剂预防事件
- 批准号:
6218497 - 财政年份:1998
- 资助金额:
$ 52.53万 - 项目类别:
PREVENTION OF EVENTS WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS
使用血管紧张素转换酶抑制剂预防事件
- 批准号:
6276139 - 财政年份:1997
- 资助金额:
$ 52.53万 - 项目类别:
ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND PROSTACYCLIN SYNTHESIS
血管紧张素转换酶抑制剂和前列环素合成
- 批准号:
3762420 - 财政年份:
- 资助金额:
$ 52.53万 - 项目类别: